Stay updated on Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial page.

Latest updates to the Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe record describes a completed Phase 2 study of cabozantinib for advanced pancreatic neuroendocrine and carcinoid tumors. It presents the study’s eligibility criteria, treatment plan, outcomes, results, and locations.SummaryDifference53%

- Check20 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check34 days agoChange DetectedThe footer revision number changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page remains a 403 Forbidden error page; its footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check62 days agoChange DetectedThe study page now displays a 403 Forbidden error, blocking access to the record. This indicates an access-control issue rather than a content update.SummaryDifference19%

Stay in the know with updates to Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial page.